FONTI, CRISTINA
FONTI, CRISTINA
DIPARTIMENTO DI MEDICINA SPECIALISTICA, DIAGNOSTICA E SPERIMENTALE (attivo dal 28/10/2011 al 31/12/2022)
Towards a personalized prediction, prevention and therapy of insomnia: gut microbiota profile can discriminate between paradoxical and objective insomnia in post-menopausal women
2024 Barone M.; Martucci M.; Sciara G.; Conte M.; Laura Smeldy Jurado Medina; Iattoni Lorenzo.; Miele F.; Fonti C.; Franceschi C.; Brigidi P.; Salvioli S.; Provini F.; Turroni S.; Santoro A.
[18F]-Fluciclovine PET/CT for preoperative nodal staging in high-risk primary prostate cancer: final results of a prospective trial
2021 Zanoni L.; Bianchi L.; Nanni C.; Pultrone C.; Giunchi F.; Bossert I.; Matti A.; Schiavina R.; Fiorentino M.; Romagnoli D.; Fonti C.; Lodi F.; D'Errico A.; Brunocilla E.; Porreca A.; Fanti S.
The Role of [18F]Fluciclovine PET/CT in the Characterization of High-Risk Primary Prostate Cancer: Comparison with [11C]Choline PET/CT and Histopathological Analysis.
2021 Zanoni L, Mei R, Bianchi L, Giunchi F, Maltoni L, Pultrone CV, Nanni C, Bossert I, Matti A, Schiavina R, Fiorentino M, Fonti C, Lodi F, D'Errico A, Brunocilla E, Fanti S.
18F-FDG PET/CT in visceral leishmaniasis: uptake patterns in the context of a multiannual outbreak in Northern Italy
2019 Zanoni L.; Varani S.; Attard L.; Morigi J.J.; Vanino E.; Ortalli M.; Fonti C.; Viale P.; Re Carla.; Fanti S.; Ambrosini V.
68Ga-PSMA-11 PET/CT in recurrent prostate cancer: efficacy in different clinical stages of PSA failure after radical therapy.
2019 Ceci F, Castellucci P, Graziani T, Farolfi A, Fonti C, Lodi F, Fanti S.
Role of 18F-FLT PET/CT in suspected recurrent or residual lymphoma: final results of a pilot prospective trial
2019 Zanoni L, Broccoli A, Lambertini A, Pellegrini C, Stefoni V, Lodi F, Fonti C, Nanni C, Zinzani PL, Fanti S